New obesity drug switch trial aims to keep weight off Long-Term
NCT ID NCT07575399
First seen May 14, 2026 · Last updated May 14, 2026
Summary
This study tests whether switching from popular weight-loss drugs (GLP-1 receptor agonists) to a new medication called maridebart cafraglutide can help adults with obesity or overweight maintain weight loss. About 300 participants who have already lost at least 10% of their body weight on a GLP-1 drug will be enrolled. The main goal is to see how body weight changes over 68 weeks, along with safety and tolerability.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY OR OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.